Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 901–1,000 of 1,000
The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2Preprint
Longhurst, A. D., Wang, K., Suresh, H. G., Ketavarapu, M., Ward, H. N., Jones, I. R., Narayan, V., Hundley, F. V., Hassan, A. Z., Boone, C. M., et al. (2024) · eLife · doi:10.7554/elife.97577.1 · Cited by 1
Möbus, V. J. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21011-2.00047-8
Clinical significance of peritoneal cancers
Nadhan, R., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824040-3.00003-0
Auger, R., Henderson, A., Izarn, F., & Allignet, B. (2024) · Journal d imagerie diagnostique et interventionnelle · doi:10.1016/j.jidi.2024.05.006
Survival of patients with de novo metastatic breast cancer
Leite, F. P. M., Fernandes, G. A., Curado, M. P., Sanches, S. M., Felippe, L. P., & Makdissi, F. B. A. (2024) · Mastology · doi:10.29289/2594539420230005
Kovalenko, E. I., & Артамонова, Е. В. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-17-7-14
Targeting CDK4 and CDK6 in hormone-dependent cancers
Bobbitt, J. R., & Keri, R. A. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.10.006
Advances in Targeted Therapy and Biomarker Research for Endocrine-Related Cancers
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5834-8
Elm’hadi, C., Zerrik, M., & Tanz, R. (2025) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-024-00947-1
“The benefit in terms of overall survival is limited to the use of ribociclib [12, 13].”
Armand, J., Kim, S., Kim, K., Son, E., Kim, M., & Yang, H. W. (2025) · eLife · doi:10.7554/elife.104545.1
Bivolarski, I. (2025) · Cureus · doi:10.7759/cureus.79174
Schneeweiss, A., Brucker, S. Y., Huebner, H., Volmer, L. L., Hack, C. C., Seitz, K., Ruebner, M., Heublein, S., Thewes, V., Lüftner, D., et al. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2453-4561
Asghar, U. S., Nadkarni, Y., Panchal, R., & Somaiah, N. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1008863
Metastasiertes hormonrezeptorpositives Mammakarzinom – die Qual der Wahl
van Mackelenbergh, M., Friedrich, M., & Maass, N. (2025) · Die Gynäkologie · doi:10.1007/s00129-025-05358-7
Cardio-Oncology and Breast Cancer Therapies
Singh, R., Patel, K. K., Xu, H., Adeniyi, A., Upshaw, J. N., Buren, P. N. V., Kaufman, P. A., Dittus, K. L., & Landry, K. K. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01311-x · Cited by 1
“%) versus AI (7.3%), and for this reason, the combination of ribociclib and tamoxifen is generally not advised [71, 72]).”
InfluentialNishina, T., Tanioka, M., Takada, K., Tsukioki, T., Takahashi, Y. K., Shien, T., & Toyooka, S. (2025) · Research Square · doi:10.21203/rs.3.rs-6616110/v1
(2025) · Journal of Clinical Oncology and Therapeutics · doi:10.47275/2690-5663-143
Chizh, G. A., Rykov, I. V., & Orlova, D. S. (2025) · Clinical Case in Oncology · doi:10.62546/3034-1477-2025-3-1-27-34
Liu, Y., Xue, N., Duan, F., Zhao, K., Liang, Y., Zhao, J., Zhang, L., Xu, Y., Zhang, Y., Wang, G., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11221-5 · Cited by 1
Sterpetti, A. V., Miceli, F., Girolamo, A. D., Iannone, I., Sapienza, P., & di Marzo, L. (2025) · Angiology · doi:10.1177/00033197251356583
Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies
Hahnen, E., Hauke, J., Gelmon, K. A., Marmé, F., Ernst, C., Martín, M., Untch, M., Bonnefoi, H. R., Knudsen, E. S., Im, S., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00588
Self-citationTünbekici, S., Gürsoy, P., & Göker, E. (2025) · Ege Tıp Dergisi · doi:10.19161/etd.1681813
Erul, E., Öksüz, N. E., Akkuş, E., Tolunay, P. K., Köksoy, E. B., & Yaşar, A. (2025) · Medicina · doi:10.3390/medicina61111960
Genetics and clinical concerns related to breast cancer research
Bhat, E. O. K., Mir, A. A., Javeed, T., & Mir, M. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27801-3.00023-5
Fu, P., Hsu, Y., Hsu, H., Lin, T., & Chung, W. (2025) · Cancer Reports · doi:10.1002/cnr2.70417
Jara, P., Ariant, M., Jiménez, R., Beranek, M. B., Herrero, B., Echavarría, I., Jerez, Y., López‐Tarruella, S., Márquez‐Rodas, I., del Monte-Millán, M., et al. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07873-6 · Cited by 1
Bouteiller, F., Gourgou, S., Bringuier, M., Galvin, A., Mailliez, A., Bertrand, N., Hung, M., Frenel, J., Massard, V., Bachelot, T., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116166
La Verde, N., Damia, G. L. M., Garrone, O., Santini, D., Fabi, A., Ciccarese, M., Generali, D. G., Nunzi, M., Poletto, E., Ferraris, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21431004
Klapp, V., Buqué, A., Bloy, N., Sato, A., Yamazaki, T., Zhou, X. K., Formenti, S. C., Galluzzi, L., & Petroni, G. (2024) · Figshare · doi:10.6084/m9.figshare.26567786
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561060
Self-citationtaweraqi, N. A., & King, R. D. (2022) · Figshare · doi:10.6084/m9.figshare.20445417
Mo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745207
Mo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745189
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561033
Self-citationMo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745222
Klapp, V., Buqué, A., Bloy, N., Sato, A., Yamazaki, T., Zhou, X. K., Formenti, S. C., Galluzzi, L., & Petroni, G. (2024) · Figshare · doi:10.6084/m9.figshare.26567783
Li, Z., Zhou, H., Xia, Z., Xia, T., Du, G., Franziska, S. D., Li, X., Zhai, X., & Jin, B. (2023) · Figshare · doi:10.6084/m9.figshare.22621921
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561042
Self-citationOlivier, T., Haslam, A., & Prasad, V. (2023) · Figshare · doi:10.6084/m9.figshare.22914616
Mo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745225
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561039
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561048
Self-citationMomal, R., Li, H., Trichelair, P., Blum, M. G. B., & Balazard, F. (2024) · Figshare · doi:10.6084/m9.figshare.26594777
Liu, H., Wang, H., Zhang, H., Yu, M., & Tang, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26027470
Li, Z., Zhou, H., Xia, Z., Xia, T., Du, G., Franziska, S. D., Li, X., Zhai, X., & Jin, B. (2023) · Figshare · doi:10.6084/m9.figshare.22621924
Mo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745195
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561045
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561054
Self-citationNeven, P., Rugo, H. S., Tolaney, S. M., Iwata, H., Toi, M., Goetz, M. P., Kaufman, P. A., Lu, Y., Haddad, N. G., Hurt, K. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16417439
Self-citationMo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745186
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561051
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561057
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561036
Self-citationNeven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petráková, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24070298
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561063
Self-citationMo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20745201
Liu, Y., Wu, J., Ji, Z., Chen, L., Zou, J., Zheng, J., Lin, W., Cai, J., Chen, Y., Zheng, D., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24070242
Chiu, J., Su, F., Joshi, M., Masuda, N., Ishikawa, T., Aruga, T., Zarate, J. P., Babbar, N., Balbin, O. A., & Yap, Y.-S. (2023) · Figshare · doi:10.6084/m9.figshare.23949790
Update Mammakarzinom 2024 Teil 2 – Patientinnen mit Frühstadien des Mammakarzinoms
Janni, W., Kolberg, H.-C., Hartkopf, A. D., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marme, F., et al. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2661-0366
Self-citationMüller, L., Schmidt, K., & Meier, P. (2021) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/1bjvmejvrj
Computational decoding of cell-cycle phase effects on cancer hallmarks across breast cancer subtypes
Castresana-Aguirre, M., Matikas, A., Lindström, L. S., & Tobin, N. P. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02208-1
Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms
Lüftner, D., Kolberg, H.-C., Hartkopf, A., Fehm, T. N., Welslau, M., Müller, V., Schütz, F., Fasching, P. A., Jackisch, C., Marme, F., et al. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2723-4918
Self-citationAnalysis of Risk Factors for Abemaciclib-Induced Diarrhea
Takeuchi, K., & Murakami, A. (2026) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.52.10 · Cited by 1
Alsuhebany, N., Alanazi, A., Alzahrani, M., Alyousef, S., Aldawish, B., Aljardan, S., Alnasr, R. A., Althumali, I., AlDoughaim, M., Alfehaid, L., et al. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s554024
“14,15 16–18 In the MONARCH trial, which led to the black box warning of abemaciclib, 19 the risk of developing VTE was 4.6% as compared to 0.6% the control group.”
InfluentialSupplements Jubilee Joint Forum 35 IMAB & 15 SEEC - Section Medicine
(2026) · Journal of IMAB - Annual Proceeding (Scientific Papers) · doi:10.5272/jimab.2025v31supplement-m
Cardio-Oncology: At the Nexus of Two 21st Century Epidemics
Radia, U. K., Ahluwalia, V., & Rosen, S. D. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm50393
Miller, J. M., Fernandez, K. C., Moore, P. I., Smith, O. G., Sharma, A., & Tanaka, A. (2025) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/mugzdk6vzb
Chan, A., Zhou, M., Arun, M., Goddard, A., & Chih, H. (2026) · The Oncologist · doi:10.1093/oncolo/oyag039 · Cited by 2
Tao, S., Yu, L., Zhang, L., Li, J., Wu, J., & Tan, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s572304
“75,76 However, previous studies supported that CDK4/6i, particularly ribociclib, exhibit QT interval prolongation risk, necessitating protocol-mandated electrocardiographic monitoring in Phase III clinical trials.”
Odabaş, H., Alomarı, O., Orman, S., Sever, N., Tüzün, E. K., Acarbay, A., Erçin, E., Aydoğan, M., Güren, A. K., Mokresh, M. E., et al. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70134
CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer
Alcantar, J. M., Chuang, F. L., & Kim, D. D. (2026) · Cureus · doi:10.7759/cureus.105839
Kumar, S., Pathak, N., & Pezo, R. C. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.04.001
Trotter, S. A., Crook, K., hamed, D. H., Wyld, L., & Brown, J. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.102964
Ji, Y., Sun, F., Sato, M., Inoue, S., Bi, Y., Zarate, J. P., & Lu, Y.-S. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.03.004
Self-citationCiblage thérapeutique de la protéine CDK6 dans les leucémies aiguës myéloïdes
Brault, L. M. (2022) · theses.fr (ABES) · doi:10.70675/26bca708z5a9az4d80z85bfz9159b330b1e8
Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo
Drabison, T., Ahmed, E. H., Colasanti, N., Weber, R. H., Sparreboom, A., & Eisenmann, E. D. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04877-x
“These agents are commonly co-administered with endocrine therapy (aromatase inhibitors [3–6], selective estrogen receptor degraders [7– 9]), chemotherapy (platinum compounds [10, 11], taxanes CYP3A, increases CDK4/6 inhibitor exposure [26], albeit ritonavir also inhibits drug transporters that may…”
Toxicités cardiovasculaires des principales thérapies ciblées orales dans les tumeurs solides
Nannini, S., Droesch, C., Schultz, É., & Moinard‐Butot, F. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.02.014
Birsin, Z., Güren, A. K., Aliyev, V., Guliyev, M., Jeral, S., Cebeci, S., Çerme, E., Günaltılı, M., Abbasov, H., Çiçek, E., et al. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s598598
Fernández-Ferreira, R., Bautista‐Piña, V., Barragán‐Dessavre, M., Cruz-Morales, G., Montaño-Hernández, J., Salas-Pérez, A., Vicuña-González, R. M., Jimenez, R. A., Moreno-López, R., García-López, S.-M., et al. (2026) · Cureus · doi:10.7759/cureus.108234
“In MONALEESA-3, involving postmenopausal women with hormone receptor-positive/HER2-negative advanced BC receiving first-line ribociclib plus fulvestrant, the longest median OS reported was 67.6 months versus 51.8 months with placebo plus fulvestrant (HR 0.67; 95% CI 0.50-0.90) [46].”
InfluentialDamaskos, C., Garmpis, N., Arkadopoulos, N. F., Michalopoulos, N. V., Garmpi, A., Papandroudis, M.-P., & Effraimidou, E. I. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103803
“CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib in combination with ET have become the current standard first-line therapy for HR+/HER2-advanced breast cancer, demonstrating significant improvements in progression-free and overall survival [9,10].”
Özbek, R. D., Aytekin, A., Yerdeş, E., & Elboğa, U. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02233-w
“Treatment with CDK4/6 inhibitors has significantly prolonged progression-free survival (PFS) and overall survival (OS) in patients with HR-positive, HER2-negative MBC, as demonstrated in numerous randomized clinical trials, including the MONALEESA-7, MONARCH, and PALOMA studies [4–9].”
Seyyar, M., Kalem, A., Salı, M., Karabuğa, B., Şahin, T. K., Dişli, A. K., Türkel, A., Karadurmuş, B., Hafızoğlu, E. Ş., Avcı, N., et al. (2026) · Current Oncology · doi:10.3390/curroncol33060365
“In routine practice, fulvestrant is frequently administered in later lines or in endocrine-resistant settings, where disease biology is more aggressive and prior endocrine exposure may reduce responsiveness [7,31].”
Ahmed, N., Okines, A. F. C., McGrath, S., Parton, M., Kipps, E., Turner, N. C., Johnston, E. W., Johnston, S. R. D., & Fotiadis, N. (2026) · Cancers · doi:10.3390/cancers18121997 · Cited by 1
“HER2-positive patients demonstrated significantly improved overall survival, consistent with the profound survival gains seen with modern HER2-targeted therapies [20,29,30].”
Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer
Ji, Y., Wang, C., Combes, F. P., Ho, Y.-Y., Fasching, P. A., Untch, M., Zarate, J. P., & Crown, J. P. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01643-3
“…statistically significant overall survival benefit in all of its phase III trials (MONALEESA-2, MONALEESA-3, and MONALEESA-7) in HR+/HER2− ABC [5–7], ribociclib plus a non-steroidal aromatase inhibitor (NSAI) has been given the highest recommendations for HR+/HER2− ABC across international…”
Çelik, S., Dursun, B., Gülcü, S., Kaya, D. M., & Öksüzoğlu, Ö. B. (2026) · Discover Oncology · doi:10.1007/s12672-026-05502-2
“Among these, ribociclib has shown consistent and robust improvements in overall survival (OS) across premenopausal and postmenopausal populations, as demonstrated in the MONALEESA-2, -3, and -7 trials [3–5].”
Gluzman, M. I., Орлова, Р. В., Topuzov, E. E., Chistyakova, E. A., & Авраменко, И. В. (2026) · Voprosy Onkologii · doi:10.37469/0507-3758-2026-72-3-of-2675
Narui, K., Miyahara, K., Uemura, Y., Yamada, A., Araki, K., Fujisawa, F., Nakayama, T., Ishikawa, T., Seki, H., Yamada, K., et al. (2026) · Breast Cancer · doi:10.1007/s12282-026-01889-6
“Moreover, abemaciclib and ribociclib combined with endocrine therapy have also been shown to significantly prolong overall survival (OS) [9–11].”
Hart, L., Rugo, H. S., Sharma, P., Sammons, S. L., Gadi, V., Mavros, P., Kaur, M., Boualam, N., Keane, C., Sopher, G., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108243
“…OS benefit in these trials (MONALEESA-3: OS HR 0.72, 95% CI 0.57-0.92, P = 0.00455; MONALEESA-7: OS HR 0.71, 95% CI 0.54-0.95, P = 0.00973) 18,19 ; however, follow-up in the MONALEESA trials continued beyond 3L, until second progression or death, whereas in this study, rwPFS2 was censored at…”
InfluentialUpadhyay, S., Khan, S., Bhardwaj, M., & Hassan, M. I. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168364
Schiza, A., Fountzilas, E., Biganzoli, L., Digkas, E., Fjermeros, K., Geisler, J., Karihtala, P., Lindman, H., Meattini, I., Muñoz-Mateu, M., et al. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.103068
Cruellas, M., Rodríguez, A., Carità, L., Seguí, E., Solís, M. C., Lema, L., Torralba, E. G., Roqué, A., Fernández-Ortega, A., Melé, M., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108335 · Cited by 1
Bidard, F., Turner, N. C., Crook, T., Adams, D., Cabel, L., Lohmann, A. E., Hurvitz, S. A., Cescon, D. W., Pistilli, B., Kuhn, E. P., et al. (2026) · Oncology The American Medical Journal · doi:10.33590/oncolamj/b8o77065
Self-citationВладимирович, С. А., & Кононенко, И. Б. (2026) · Journal of Modern Oncology · doi:10.26442/18151434.2026.2.203708
Tohumcuoğlu, M., Yetişir, A. E., Cinkara, Z. U., Türker, M., Duşgün, A., Mirili, C., Tazeoğlu, D., Köşeci, T., Oğul, A., & Büyükşimşek, M. (2026) · Medicina · doi:10.3390/medicina62081470
Popovic, L., Popovic, M., & Matovina-Brko, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30050-9.00053-9
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.